BR112012008951A2 - tratamento de neurotoxidez associada com combinações de 5-fu ou seus profármacos e inibidores de dpd - Google Patents

tratamento de neurotoxidez associada com combinações de 5-fu ou seus profármacos e inibidores de dpd

Info

Publication number
BR112012008951A2
BR112012008951A2 BR112012008951A BR112012008951A BR112012008951A2 BR 112012008951 A2 BR112012008951 A2 BR 112012008951A2 BR 112012008951 A BR112012008951 A BR 112012008951A BR 112012008951 A BR112012008951 A BR 112012008951A BR 112012008951 A2 BR112012008951 A2 BR 112012008951A2
Authority
BR
Brazil
Prior art keywords
prodrugs
dpd
combinations
treatment
patient
Prior art date
Application number
BR112012008951A
Other languages
English (en)
Portuguese (pt)
Inventor
Spector Thomas
Original Assignee
Adherex Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adherex Tech Inc filed Critical Adherex Tech Inc
Publication of BR112012008951A2 publication Critical patent/BR112012008951A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112012008951A 2009-10-14 2010-10-14 tratamento de neurotoxidez associada com combinações de 5-fu ou seus profármacos e inibidores de dpd BR112012008951A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25144909P 2009-10-14 2009-10-14
PCT/US2010/052734 WO2011047195A1 (en) 2009-10-14 2010-10-14 Treating neurotoxicity associated with combinations of 5 - fu or its prodrugs and dpd inhibitors

Publications (1)

Publication Number Publication Date
BR112012008951A2 true BR112012008951A2 (pt) 2019-09-24

Family

ID=43466528

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012008951A BR112012008951A2 (pt) 2009-10-14 2010-10-14 tratamento de neurotoxidez associada com combinações de 5-fu ou seus profármacos e inibidores de dpd

Country Status (14)

Country Link
US (1) US8658618B2 (cg-RX-API-DMAC7.html)
EP (1) EP2488182B1 (cg-RX-API-DMAC7.html)
JP (2) JP2013508293A (cg-RX-API-DMAC7.html)
KR (1) KR20120127709A (cg-RX-API-DMAC7.html)
CN (1) CN102811721A (cg-RX-API-DMAC7.html)
AU (1) AU2010306698B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012008951A2 (cg-RX-API-DMAC7.html)
CA (1) CA2777546C (cg-RX-API-DMAC7.html)
CO (1) CO6541596A2 (cg-RX-API-DMAC7.html)
EA (1) EA201270551A1 (cg-RX-API-DMAC7.html)
ES (1) ES2644237T3 (cg-RX-API-DMAC7.html)
IL (1) IL219179A0 (cg-RX-API-DMAC7.html)
MX (1) MX2012004383A (cg-RX-API-DMAC7.html)
WO (1) WO2011047195A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089004A1 (en) * 2012-12-04 2014-06-12 Adherex Technologies, Inc. Methods for treating 5-fluorouracil prodrug non-responsive cancer patients
CN106692173A (zh) * 2015-11-18 2017-05-24 北京诺普德医药科技有限公司 一种抗肿瘤复方组合物及其应用
US20240180910A1 (en) * 2022-12-06 2024-06-06 Elion Oncology, Inc. Method for treating cancer with a chemotherapeutic modifier
WO2025015267A1 (en) * 2023-07-13 2025-01-16 Processa Pharmaceuticals, Inc. Methods of personalizing cancer treatment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5687599A (en) 1979-12-19 1981-07-16 Yamasa Shoyu Co Ltd E 55 22halogenovinyl arabinofuranosyluracil and its preparation
GB8629892D0 (en) 1986-12-15 1987-01-28 Wellcome Found Antiviral compounds
US5157114A (en) 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
ES2111569T3 (es) * 1990-07-19 1998-03-16 Wellcome Found Inactivadores de enzimas.
GB9020930D0 (en) 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations
US5476855A (en) 1993-11-02 1995-12-19 Mahmoud H. el Kouni Enzyme inhibitors, their synthesis and methods for use
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20040028687A1 (en) * 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
AU2005311730B2 (en) * 2004-12-03 2011-11-17 Adherex Technologies, Inc. Methods for administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs

Also Published As

Publication number Publication date
EA201270551A1 (ru) 2012-12-28
KR20120127709A (ko) 2012-11-23
MX2012004383A (es) 2012-08-23
CN102811721A (zh) 2012-12-05
EP2488182B1 (en) 2017-07-19
CA2777546A1 (en) 2011-04-21
EP2488182A1 (en) 2012-08-22
WO2011047195A1 (en) 2011-04-21
CA2777546C (en) 2019-11-05
JP2016014051A (ja) 2016-01-28
AU2010306698B2 (en) 2016-05-26
IL219179A0 (en) 2012-06-28
AU2010306698A1 (en) 2012-05-17
US20110130359A1 (en) 2011-06-02
CO6541596A2 (es) 2012-10-16
JP2013508293A (ja) 2013-03-07
US8658618B2 (en) 2014-02-25
ES2644237T3 (es) 2017-11-28

Similar Documents

Publication Publication Date Title
ECSP099376A (es) Inhibidores de la actividad de la akt
GEP20166455B (en) Methods of administering pirfenidone therapy
BR112015012536A2 (pt) tratamento de câncer com inibidores heterocíclicos da glutaminase
CY1117440T1 (el) Συτηκτα παραγωγα ιμιδαζολης ως αναστολεις toy ido
MX2009012197A (es) Metodos para tratamiento de ulceras en la piel.
BR112023000687A2 (pt) Métodos e combinações de inibidores de kat6 para o tratamento de câncer
WO2008147482A3 (en) Methods and compositions for improving immune responses
EP4512480A3 (en) Cancer treatments using combinations of cdk and erk inhibitors
PH12014501880A1 (en) Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
MX2012000817A (es) Tratamiento para desordenes del higado con inhibidores pi3k.
MX365007B (es) Uso de acido lipasa lisosomal para tratar la dificiencia de acido lipasa lisosomal en pacientes.
EA201491694A1 (ru) Лечение рака ингибиторами tor киназы
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
EP3466423A3 (en) Treatment of cancer with tor kinase inhibitors
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
NI201400110A (es) Tratamiento del cáncer con inhibidores tor cinasa
EP2558102A4 (en) SYNERGISTIC INTERACTION OF AT LEAST ONE COMPONENT OF VITAMIN E AND TYROSINASE INHIBITORS FOR DERMATOLOGICAL APPLICATIONS
HK1221144A1 (zh) 用於治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
BR112016004118A2 (pt) uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
TR201909412T4 (tr) Restenozun önlenmesi veya tedavisi için bileşikler ve yöntemler.
MX347927B (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
SG10201810575WA (en) Treatment of prostate cancer with tor kinase inhibitors
BR112019002945A2 (pt) terapia de combinação para o tratamento de câncer pancreático
UY32546A (es) Composiciones y metodos para tratar cancer
MX2019013862A (es) Terapia de combinacion.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.